For an adult trying to track whether a new training block is actually shifting body fat, the standard of care is awkward. A DEXA scan at a clinic or specialty gym runs roughly $50 to $150 per session and requires an appointment. Bioelectrical impedance scales sold for home use are cheap but drift with hydration. Hydrostatic weighing, the older gold standard, is hard to find outside research centers. For most patients and most gym members, body composition simply is not measured at all between an annual physical and the next one, and weight on a bathroom scale is the proxy. That gap is where Spren is trying to wedge itself in, by asking users to point a smartphone camera at themselves instead.
Spren, headquartered in Asheville, North Carolina, sells SDKs and an API that let fitness and wellness apps embed camera-based readings of heart rate variability, respiration rate, body fat percentage, and a handful of derived scores such as recovery and acute mental stress [Spren Docs]. The company was founded in 2014 as Elite HRV by Jason Moore and rebranded as Spren as the product expanded beyond heart rate variability into computer vision body scans [Athletech News]. Moore is CEO, co-founder Vivek Menon, a Dartmouth alum who has been with the company since 2017, serves as COO [Crunchbase][The Org].
The commercial bet is B2B2C. Rather than fight Apple, Fitbit, Whoop, or Oura for wrist real estate, Spren licenses its computer vision stack to brands that already have an app and a user base. The most visible deployment to date is with Snap Fitness, which announced it would roll out AI body composition scanning and personalized nutrition through Spren across more than 1,100 gyms worldwide [FITT Insider]. For a gym chain, the pitch is straightforward: give members a measurable progress metric beyond the scale, increase app engagement, and do it without buying a DEXA machine for every location.
The round that funded this push closed in October 2022, when Spren raised $11.3 million in seed capital led by Drive by DraftKings, with participation from Boston Seed Capital, Karlani Capital, Permit Ventures, High Country Impact Fund, and angel checks from Eli Manning and Theo Epstein [Crunchbase, Oct 2022][Benzinga, Oct 2022]. The investor mix is unusual for a healthtech seed and tells you something about the go-to-market: Spren is being positioned first as a sports and wellness infrastructure play, not as a regulated medical device.
Seed round (Oct 2022) | 11.3 | $M
Global wellness market cited | 1500000 | $M
The upside case rests on two trends. First, the wellness category that Spren is selling into is enormous, the company cited a $1.5 trillion global wellness market in its funding announcement [PRWeb, Oct 2022]. Second, the substitution math is favorable if the accuracy holds. Spren says its body composition measurement reaches a 0.95 correlation with gold-standard methods and a 2.6% mean absolute error, validated against DXA, underwater weighing, and 5-compartment models in work conducted with Pennington Biomedical Research Center and university partners across more than 240 subjects [Spren.com]. Those figures are company-disclosed and the underlying papers should be read directly by anyone making a clinical decision, but a sub-3% error band, if it generalizes, is meaningful for a measurement that today requires a clinic visit.
It is worth being precise about regulatory posture. Spren is not, based on its public materials, marketing the camera scan as a diagnostic device under FDA clearance. The body composition and HRV readouts are presented as wellness and fitness insights, which is the same regulatory lane occupied by most consumer wearables. That keeps time-to-market short and lets partners like Snap Fitness deploy quickly. It also means the burden of proof on accuracy lives in peer-reviewed validation studies and partner trust rather than in a 510(k) file. For the diabetes prevention program Spren also lists on its site, the regulatory and reimbursement context is more involved, since CDC-recognized DPP standards and payer contracting come into play [Spren.com].
The team has been working on this problem for a decade in one form or another, which matters in a category where the hard part is not the model but the data. Moore's background spans biomarker work and athletic training, and the Elite HRV product gave the company years of physiological signal data before the pivot into computer vision [FITT Insider]. The Snap Fitness partnership is the most concrete commercial proof point in the public record and the kind of distribution deal a seed-stage infrastructure company typically needs to justify a Series A.
What bears say, and what bulls answer
The credible concern is accuracy under field conditions. Camera-based physiological measurement has a known sensitivity to lighting, skin tone, and motion, and validation cohorts in a research setting are not the same as a member taking a scan in a fluorescent-lit locker room. Bears will note that Spren's headline 0.95 correlation and 2.6% error figures are drawn from company-published validation work [Spren.com] and that broader independent replication across diverse populations is what would move the category. Bulls answer that the validation was conducted with Pennington Biomedical, a recognized obesity and metabolism research center, and that the Snap Fitness rollout across 1,100-plus locations is itself a real-world stress test that will produce the kind of cross-population data that strengthens or weakens the claim [FITT Insider]. Either way, the next round of published research will matter more than the marketing page.
What to watch
Over the next twelve months, the milestones to track are concrete. First, additional peer-reviewed publications on the body composition model, ideally with cohorts that explicitly report performance across skin tones and body types. Second, the depth of the Snap Fitness integration: scan completion rates, member retention deltas, and whether the chain expands the use case into nutrition coaching as announced. Third, new SDK customers beyond gyms, particularly any digital health or chronic care company willing to put a camera scan inside a clinical workflow. And fourth, the shape of the next financing. The seed closed three years ago, and a Series A priced off real partner revenue would tell the market that the B2B2C wedge is converting. For patients living with obesity, prediabetes, or simply the quiet frustration of not knowing whether their training is working, a phone-based measurement that holds up under scrutiny would be a genuinely useful addition to the standard of care.